Astellas Pharma Europe achieved the first sales of DIFICLIR (fidaxomicin) tablets, triggering a $12.6 million milestone payment to Optimer Pharmaceuticals, Inc. Under the 2011 collaboration and license agreement, Optimer granted Astellas development and commercialization rights in Europe and certain other countries in the Middle East, Africa and the Commonwealth of Independent States (CIS). The drug was granted Marketing Authorization by the European Commission for the treatment of adults with C...